Form 4: Autonomix CFO Cancels Options for Severance

Autonomix Medical's CFO, Trent N. Smith, cancelled stock options for 32,655 shares in exchange for three months of additional severance.

Summary

• Trent N. Smith, Chief Financial Officer (CFO) of Autonomix Medical, Inc. (AMIX), reported the cancellation of two stock options on August 11, 2025.
• The cancelled options included 11,405 shares with an exercise price of $26.56 and 21,250 shares with an exercise price of $40.
• These option amounts and exercise prices were previously adjusted due to a 1-for-20 reverse stock split effective October 25, 2024.
• The options were cancelled by mutual agreement between Mr. Smith and Autonomix Medical, Inc.
• As consideration for the cancellation, Mr. Smith received an additional three months of severance.
• Following these transactions, Mr. Smith beneficially owns 22,500 derivative securities related to the first option type and 1,250 derivative securities related to the second option type, which were not part of this cancellation.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While the company reduces potential dilution, it incurs severance costs. For the CFO, giving up equity upside, even with severance, can be seen as a negative, especially if the options were in-the-money or had significant future potential.

Positives

• The company reduced potential future dilution by cancelling 32,655 outstanding stock options.
• The CFO received additional severance, providing immediate financial benefit.

Negatives

• The CFO forfeited potential future equity upside from 32,655 stock options.
• The company incurred additional severance costs.

Risks

• The cancellation of executive stock options, even with severance, could signal potential changes in executive compensation strategy or future management transitions, which may impact investor confidence.
• The transaction date of August 11, 2025, being in the future relative to the filing date of August 13, 2025, is unusual for a Form 4 and could indicate a pre-arranged future disposition or a clerical error.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the reported transaction details and future option expiration dates.

Industry Context

Form 4 filings are standard disclosures for changes in beneficial ownership by company insiders. Option cancellations can occur for various reasons, including executive departures, renegotiated compensation packages, or company efforts to manage equity dilution. This specific transaction reflects a change in executive compensation structure for the CFO.

Stakeholder Impact

• Shareholders: Potential future dilution from these specific options is reduced, but the company incurs additional severance costs.
• CFO: Receives immediate financial benefit from severance but forfeits potential long-term equity gains from the cancelled options.

Key Dates

Recommendation

This Form 4 filing details a specific executive compensation transaction (option cancellation for severance) and does not provide sufficient comprehensive financial or strategic information about Autonomix Medical, Inc. to warrant a strong buy or sell recommendation. It is a data point that should be considered within a broader analysis of the company's performance, management stability, and market conditions.

Keywords

Autonomix Medical, AMIX, SEC Form 4, stock options, CFO, Trent Smith, severance, executive compensation, reverse stock split, equity disposition